Cannabis adulterated with the synthetic cannabinoid receptor agonist MDMB-4en-PINACA and the role of European drug checking services.

[1]  A. Benschop,et al.  Visitors of the Dutch drug checking services: Profile and drug use experience. , 2021, The International journal on drug policy.

[2]  F. Measham,et al.  Intentions, actions and outcomes: A follow up survey on harm reduction practices after using an English festival drug checking service. , 2021, The International journal on drug policy.

[3]  J. Rehm,et al.  Use of alcohol, tobacco, cannabis, and other substances during the first wave of the SARS-CoV-2 pandemic in Europe: a survey on 36,000 European substance users , 2021, Substance Abuse Treatment, Prevention, and Policy.

[4]  W. Hall,et al.  Cannabis and COVID-19: Reasons for Concern , 2020, Frontiers in Psychiatry.

[5]  R Goncalves,et al.  Suitability of infrared spectroscopy for drug checking in harm reduction centres. , 2020, The International journal on drug policy.

[6]  M. di Forti,et al.  Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis. , 2020, Addiction.

[7]  M. Barratt,et al.  Evaluation of a drug checking service at a large scale electronic music festival in Portugal. , 2019, The International journal on drug policy.

[8]  P. Griffiths,et al.  Increasing potency and price of cannabis in Europe, 2006–16 , 2019, Addiction.

[9]  Daniel Martins,et al.  Drug testing in Europe: monitoring results of the Trans European Drug Information (TEDI) project. , 2017, Drug testing and analysis.

[10]  M. Connor,et al.  The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins. , 2018, Handbook of experimental pharmacology.